Literature DB >> 32069215

HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: MEN1-related pancreatic NETs: identification of unmet clinical needs and future directives.

C R C Pieterman1,2, S M Sadowski3, J E Maxwell4, M H G Katz4, K E Lines5, C M Heaphy6, A Tirosh7, J E Blau8, N D Perrier1, M A Lewis9,10, J P Metzcar11,12, D M Halperin13, R V Thakker5, G D Valk2.   

Abstract

The PanNET Working Group of the 16th International Multiple Endocrine Neoplasia Workshop (MEN2019) convened in Houston, TX, USA, 27-29 March 2019 to discuss key unmet clinical needs related to PanNET in the context of MEN1, with a special focus on non-functioning (nf)-PanNETs. The participants represented a broad range of medical scientists as well as representatives from patient organizations, pharmaceutical industry and research societies. In a case-based approach, participants addressed early detection, surveillance, prognostic factors and management of localized and advanced disease. For each topic, after a review of current evidence, key unmet clinical needs and future research directives to make meaningful progress for MEN1 patients with nf-PanNETs were identified. International multi-institutional collaboration is needed for adequately sized studies and validation of findings in independent datasets. Collaboration between basic, translational and clinical scientists is paramount to establishing a translational science approach. In addition, bringing clinicians, scientists and patients together improves the prioritization of research goals, assures a patient-centered approach and maximizes patient involvement. It was concluded that collaboration, research infrastructure, methodologic and reporting rigor are essential to any translational science effort. The highest priority for nf-PanNETs in MEN1 syndrome are (1) the development of a data and biospecimen collection architecture that is uniform across all MEN1 centers, (2) unified strategies for diagnosis and follow-up of incident and prevalent nf-PanNETs, (3) non-invasive detection of individual nf-PanNETs that have an increased risk of metastasis, (4) chemoprevention clinical trials driven by basic research studies and (5) therapeutic targets for advanced disease based on biologically plausible mechanisms.

Entities:  

Keywords:  MEN1; conference proceeding; management; multiple endocrine neoplasia type 1; pancreatic neuroendocrine tumor; research infrastructure; risk stratification; surveillance; treatment; unmet clinical needs

Year:  2020        PMID: 32069215     DOI: 10.1530/ERC-19-0441

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  5 in total

1.  Prognosis after surgery for multiple endocrine neoplasia type 1-related pancreatic neuroendocrine tumors: Functionality matters.

Authors:  Dirk-Jan van Beek; Sjoerd Nell; Helena M Verkooijen; Inne H M Borel Rinkes; Gerlof D Valk; Menno R Vriens
Journal:  Surgery       Date:  2020-11-19       Impact factor: 4.348

2.  Plasma Polyamines as an Additional to Imaging Biomarker in MEN1 Patients With Duodenopancreatic Neuroendocrine Tumors.

Authors:  Eva Kassi; Gregory Kaltsas
Journal:  J Clin Endocrinol Metab       Date:  2022-01-18       Impact factor: 5.958

Review 3.  Parathyroid Carcinoma All-In-One, a Rare Life-Threatening Case With Multiple Systemic Manifestations: Case Report and Review of the Literature.

Authors:  Lorenzo Zelano; Pietro Locantore; Carlo Antonio Rota; Caterina Policola; Andrea Corsello; Esther Diana Rossi; Vittoria Rufini; Luca Zagaria; Marco Raffaelli; Alfredo Pontecorvi
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-07       Impact factor: 6.055

Review 4.  Multiple Endocrine Neoplasia Type 1: Latest Insights.

Authors:  Maria Luisa Brandi; Sunita K Agarwal; Nancy D Perrier; Kate E Lines; Gerlof D Valk; Rajesh V Thakker
Journal:  Endocr Rev       Date:  2021-03-15       Impact factor: 19.871

5.  A Blood-based Polyamine Signature Associated With MEN1 Duodenopancreatic Neuroendocrine Tumor Progression.

Authors:  Johannes F Fahrmann; Amanda R Wasylishen; Carolina R C Pieterman; Ehsan Irajizad; Jody Vykoukal; Eunice Murage; Ranran Wu; Jennifer B Dennison; Hansini Krishna; Christine B Peterson; Guillermina Lozano; Hua Zhao; Kim-Anh Do; Daniel M Halperin; Sunita K Agarwal; Jenny E Blau; Jaydira Del Rivero; Naris Nilubol; Mary F Walter; James M Welch; Lee S Weinstein; Menno R Vriens; Rachel S van Leeuwaarde; Mark J C van Treijen; Gerlof D Valk; Nancy D Perrier; Samir M Hanash
Journal:  J Clin Endocrinol Metab       Date:  2021-11-19       Impact factor: 6.134

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.